Viking Therapeutics, Inc. – NASDAQ:VKTX
Viking Therapeutics stock price today
$24.4
-16.75
-40.72%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
Viking Therapeutics stock price monthly change
-28.02%
month
Viking Therapeutics stock price quarterly change
-28.02%
quarter
Viking Therapeutics stock price yearly change
+109.57%
year
Viking Therapeutics key metrics
Market Cap | 4.56B |
Enterprise value | 1.32B |
P/E | -19.23 |
EV/Sales | N/A |
EV/EBITDA | -19.82 |
Price/Sales | N/A |
Price/Book | 9.35 |
PEG ratio | 1.02 |
EPS | -0.92 |
Revenue | N/A |
EBITDA | -114.21M |
Income | -93.72M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeViking Therapeutics stock price history
Viking Therapeutics stock forecast
Viking Therapeutics financial statements
Average Price Target
$98
Potential upside: 301.63%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -19.22M | |
|---|---|---|---|
| Sep 2023 | 0 | -22.53M | |
| Dec 2023 | 436K | -24.60M | -5643.35% |
| Mar 2024 | 0 | -27.35M |
| 2023-04-26 | -0.26042 | -0.25 |
|---|
| Jun 2023 | 400693000 | 14.57M | 3.64% |
|---|---|---|---|
| Sep 2023 | 382663000 | 14.42M | 3.77% |
| Dec 2023 | 368490000 | 20.07M | 5.45% |
| Mar 2024 | 967518000 | 33.62M | 3.48% |
| Jun 2023 | -11.43M | -204.48M | 267.07M |
|---|---|---|---|
| Sep 2023 | -19.65M | -12.53M | -74K |
| Dec 2023 | -17.64M | 35.73M | 188K |
| Mar 2024 | -6.13M | -459.79M | 606.03M |
Viking Therapeutics alternative data
| Sep 2023 | 22 |
|---|---|
| Oct 2023 | 22 |
| Nov 2023 | 23 |
| Dec 2023 | 23 |
| Jan 2024 | 23 |
| Feb 2024 | 23 |
| Mar 2024 | 27 |
| Apr 2024 | 27 |
| May 2024 | 28 |
| Jun 2024 | 28 |
| Jul 2024 | 28 |
Viking Therapeutics other data
43.23%
-7.22%
of VKTX is owned by hedge funds
130
-1
31.01M
-5.17M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 0 | 524804 |
| Apr 2023 | 0 | 476872 |
| May 2023 | 0 | 101000 |
| Jan 2024 | 0 | 165000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | LIAN BRIAN director, officer.. | Common Stock, par value $0.00001 per share | 85,000 | $1.23 | $104,550 | ||
Option | LIAN BRIAN director, officer.. | Common Stock, par value $0.00001 per share | 85,000 | $1.23 | $104,550 | ||
Sale | LIAN BRIAN director, officer.. | Common Stock, par value $0.00001 per share | 40,000 | $24.45 | $978,000 | ||
Sale | LIAN BRIAN director, officer.. | Common Stock, par value $0.00001 per share | 40,000 | $24.45 | $978,000 | ||
Sale | LIAN BRIAN director, officer.. | Common Stock, par value $0.00001 per share | 45,000 | $24.95 | $1,122,750 | ||
Sale | LIAN BRIAN director, officer.. | Common Stock, par value $0.00001 per share | 45,000 | $24.95 | $1,122,750 | ||
Option | LIAN BRIAN director, officer.. | Stock Option (right to buy) | 85,000 | $1.23 | $104,550 | ||
Option | LIAN BRIAN director, officer.. | Stock Option (right to buy) | 85,000 | $1.23 | $104,550 | ||
Option | LIAN BRIAN director, officer.. | Common Stock, par value $0.00001 per share | 35,000 | $1.23 | $43,050 | ||
Option | LIAN BRIAN director, officer.. | Common Stock, par value $0.00001 per share | 35,000 | $1.23 | $43,050 |
| Quarter | Transcript |
|---|---|
| Q1 2024 24 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2024 7 Feb 2024 | Q4 2024 Earnings Call Transcript |
| Q3 2023 25 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 26 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Brian Lian Ph.D. (1966) Pres, Chief Executive Officer & Director | $878,000 |
Viking Therapeutics: Still On Track
Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential
Viking Therapeutics: Buy It For The Future And Ignore The Noise
Viking Therapeutics: Weight-Loss Story Remains Intact
Viking Therapeutics: A High Potential Biotech Play With Manageable Risks
Viking Therapeutics: Near-Term Catalysts And Competitor Readouts
-
What's the price of Viking Therapeutics stock today?
One share of Viking Therapeutics stock can currently be purchased for approximately $24.4.
-
When is Viking Therapeutics's next earnings date?
Unfortunately, Viking Therapeutics's (VKTX) next earnings date is currently unknown.
-
Does Viking Therapeutics pay dividends?
No, Viking Therapeutics does not pay dividends.
-
How much money does Viking Therapeutics make?
Viking Therapeutics has a market capitalization of 4.56B. Viking Therapeutics made a loss 85.9M US dollars in net income (profit) last year or -$0.25 on an earnings per share basis.
-
What is Viking Therapeutics's stock symbol?
Viking Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "VKTX".
-
What is Viking Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Viking Therapeutics?
Shares of Viking Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Viking Therapeutics's key executives?
Viking Therapeutics's management team includes the following people:
- Dr. Brian Lian Ph.D. Pres, Chief Executive Officer & Director(age: 59, pay: $878,000)
-
How many employees does Viking Therapeutics have?
As Jul 2024, Viking Therapeutics employs 28 workers, which is 4% more then previous quarter.
-
When Viking Therapeutics went public?
Viking Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 28 Apr 2015.
-
What is Viking Therapeutics's official website?
The official website for Viking Therapeutics is vikingtherapeutics.com.
-
Where are Viking Therapeutics's headquarters?
Viking Therapeutics is headquartered at 9920 Pacific Heights Boulevard, San Diego, CA.
-
How can i contact Viking Therapeutics?
Viking Therapeutics's mailing address is 9920 Pacific Heights Boulevard, San Diego, CA and company can be reached via phone at 858 704 4660.
-
What is Viking Therapeutics stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Viking Therapeutics in the last 12 months, the avarage price target is $98. The average price target represents a 301.63% change from the last price of $24.4.
Viking Therapeutics company profile:
Viking Therapeutics, Inc.
vikingtherapeutics.comExchange:
NASDAQ
Full time employees:
30
Industry:
Biotechnology
Sector:
Healthcare
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
9920 Pacific Heights Boulevard
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001607678
ISIN: US92686J1060
CUSIP: 92686J106
